Get started
Oncopeptides ABOncopeptides ABOncopeptides AB

Oncopeptides AB

No trades
OverviewFinancialsNewsMindsForecastsSeasonalsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪80.45 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1040 EUR
Net income (FY)
‪−24.74 M‬ EUR
Revenue (FY)
‪2.75 M‬ EUR
Shares float
‪164.80 M‬
Beta (1Y)
0.31

Employees


Employees (FY)
66
Change (1Y)
+9 +15.79%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Oncopeptides AB


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sofia Heigis
Website
oncopeptides.se
Headquarters
Stockholm
Founded
2000
Identifiers
2
ISIN SE0009414576
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.

Check out other big names from the same industry as OND.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Oncopeptides AB stocks are traded under the ticker OND.
We've gathered analysts' opinions on Oncopeptides AB future price: according to them, OND price has a max estimate of 0.47 EUR and a min estimate of 0.42 EUR. Watch OND chart and read a more detailed Oncopeptides AB stock forecast: see what analysts think of Oncopeptides AB and suggest that you do with its stocks.
OND reached its all-time high on Mar 1, 2021 with the price of 13.4353 EUR, and its all-time low was 0.1044 EUR and was reached on Jan 24, 2025. View more price dynamics on OND chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Oncopeptides AB financials in yearly and quarterly reports right on TradingView.
Oncopeptides AB is going to release the next earnings report on Feb 19, 2026. Keep track of upcoming events with our Earnings Calendar.
Oncopeptides AB revenue for the last quarter amounts to ‪1.81 M‬ EUR, despite the estimated figure of ‪2.89 M‬ EUR. In the next quarter, revenue is expected to reach ‪2.38 M‬ EUR.
OND net income for the last quarter is ‪−5.50 M‬ EUR, while the quarter before that showed ‪−5.61 M‬ EUR of net income which accounts for 2.09% change. Track more Oncopeptides AB financial stats to get the full picture.
No, OND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 28, 2026, the company has 66 employees. See our rating of the largest employees — is Oncopeptides AB on this list?
Like other stocks, OND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncopeptides AB stock right from TradingView charts — choose your broker and connect to your account.